September 4, 2013—The Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) has published its first quarterly list of orphan drugs subject to exclusion from 340B pricing in certain circumstances.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)